In June, Syapse—a company that works with health systems to implement precision medicine across its organizations—took the next step in leading the shift toward precision medicine by launching the Syapse Precision Medicine Council.
In June, Syapse—a company that works with health systems to implement precision medicine across its organizations—took the next step in leading the shift toward precision medicine by launching the Syapse Precision Medicine Council. The council consists of oncology, operations, and research leaders from health systems dedicated to advancing precision medicine through sharing strategies and insights in order to identify best practices.
Dennis Shin, chief commercial officer of Syapse, discussed the formation of the council, how it plans to disrupt the current precision oncology landscape, and what he sees for the future of the council.
To listen, login to the website.
Listen above or through one of these podcast services:
iTunes: http://apple.co/2eYWTss?rel=0"
TuneIn: http://bit.ly/2gv7iwj?rel=0"
Stitcher: http://bit.ly/2gCqtFg?rel=0"
Syapse, Roche Team Up to Advance Precision Medicine in Oncology
Syapse Looks to Expand Precision Medicine Partnerships With New CEO
Oncologists Are Crucial to Advancing Precision Medicine
Precision Health AI Launches Platform to Deliver Data-Driven Insights in Oncology
Using Health IT to Increase Medication Adherence and Enhance Precision Medicine
Read more about Syapse and precision oncology:
Exploring Medicare Advantage Prior Authorization Variations
March 26th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the March 2024 issue of The American Journal of Managed Care® about their findings on variations in prior authorization use across Medicare Advantage plans.
Listen
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen
FDA Grants Accelerated Approval to Ponatinib Plus Chemotherapy in First-Line Ph+ ALL
March 19th 2024The FDA has granted accelerated approval to ponatinib (Iclusig) plus chemotherapy for the first-line treatment pf Philadelphia chromosome–positive acute lymphoblastic leukemia (Ph+ ALL).
Read More